By: Jonathan Saltzman
The two large health care organizations are blaming each other for an impasse in negotiations over reimbursement rates.
Jonathan Saltzman is a reporter at The Boston Globe, where he covers biotechnology and the life sciences. With a strong background in health and wellness topics, he has reported on issues ranging from the FDA to the impacts of the Coronavirus, while also exploring the biotech market in Massachusetts. Saltzman has been featured in STAT and the Boston Globe Technology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Boston, United States (Local)
Not enough data
Jonathan Saltzman's main focus is on the healthcare and pharmaceutical industry, particularly in the Massachusetts and Boston area. He heavily relies on press releases, data citations, government announcements, and private sector announcements for his articles.
If you are reaching out to Jonathan with a pitch or as a potential source for an article, it would be beneficial to provide newsworthy information related to biotech developments such as FDA approvals of novel therapies or acquisitions within pharmaceutical companies. Personal insights into business strategies within the healthcare sector may also pique his interest. Additionally, providing relevant data or evidence-based analysis could make your outreach more compelling given Jonathan's reliance on cited data in his coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .